With FDA approval of the ultra-rare disease treatment Strensiq (asfotase alfa), Alexion Pharmaceuticals Inc. finds itself breathing the rarified air of companies who have grabbed hold of a coveted priority review voucher.
However, Alexion's announced plans not to sell the voucher but, rather, to redeem it in the next few years on one of its own pipeline products may be considered surprising for a company focused on developing treatments for patients with very rare diseases and/or high unmet needs – the